# A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases

> **NCT02639260** · PHASE1 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 10 (actual)

## Conditions studied

- Kidney Disease

## Interventions

- **DRUG:** N-acetyl D-mannosamine

## Key facts

- **NCT ID:** NCT02639260
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-07
- **Primary completion:** 2018-06-05
- **Final completion:** 2018-06-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639260, "A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02639260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*